13 October 2017

New verification system in the fight against falsified medicinal products

Falsified medicinal products are an increasing problem, which is a threat to patient safety and the pharmaceutical industry. On 9 February 2019, a new verification system will come into force making it possible to verify a medicinal product's authenticity and prevent the flow of falsified medicinal products within the legal supply chain.

The new verification system is a consequence of the new directive on falsified medicinal products (2011/62/EU) and the Commission Delegated Regulation (EU) 2016/161 on supplementary rules for the safety features printed on the packaging of medicinal products for human use.

SPECIAL SAFETY FEATURES MUST PREVENT FALSIFIED MEDICINAL PRODUCTS WITHIN THE LEGAL SUPPLY CHAIN

The purpose of the new rules is to prevent that falsified medicinal products enter the legal supply chain, i.e. the supply chain consisting of players holding a licence under the Medicines Act to manufacture, distribute, sell and pack medicinal products. This includes licensed manufacturers, wholesalers, parallel distributors and pharmacies.

According to the new rules, all prescription-only medicinal products and certain types of non-prescription medicinal products must have special safety features on the packaging:

  • A unique 2D bar code (as opposed to the linear bar code used today) making it possible to identify the specific packaging.
  • A safety sealing making it easy to see if the sealing has been broken.  

In general, the rules apply to all prescription-only medicinal products. However, there are some exemptions, which are listed in appendix 1 to the regulation. The rules also apply to some types of non-prescription medicinal products, which are listed in appendix II to the regulation. Appendices I and II.

DEFINITION OF A FALSIFIED MEDICINAL PRODUCT

In the Directive, a falsified medicinal product is defined as a medicinal product with a false representation of its identity (for instance packaging, labelling, name or composition), its source (for instance holder of the marketing authorisation, manufacturer or country of origin) or its history (for instance records and documents concerning the distribution channels used).

VERIFICATION PROCEDURE

The verification system consists of a European and a Danish database. In February 2015, the European Medicines Verification Organisation (EMVO) was established for the purpose of administering, operating and controlling the European verification system (EU hub/EMVS). However, the Danish database (DMVS) is administered by the Danish Medicine Verification Organisation (DMVO), which was established in November 2016 to ensure the implementation of the new rules in Denmark.

Manufacturers of medicinal products, including manufacturers of original products and generic manufacturers, and parallel importers must add a unique bar code on all packaging. According to the verification system, the manufacturer or the parallel importer then uploads the bar codes’ content to the EMVS, which will then store the information on all packaging sold in the EU. The information is sent from the European database to the national databases.

Pharmacies may not hand out medicinal products to citizens before the products have been verified. The verification takes place in the European database via the national databases as soon as the pharmacy scans the bar code. If the scan shows that the medicinal product has not been sold before or appears somewhere else in the system, the product is genuine and may be handed out to the citizen.

If the product does not appear in the system, or the scan shows that the product has already been sold somewhere else in the EU, it is falsified. The medicinal product may therefore not be handed out and must be handled according to a special procedure.

In order to be able to continue to sell medicinal products after 9 February 2019, the manufacturers and parallel importers must upload their product data to the EMVS and conclude an agreement with the EMVO. If the manufacturers and parallel importers have a marketing authorisation in Denmark, they must be registered and conclude an agreement with the DMVO in order to sell the medicinal products on the Danish market.

MANUFACTURERS AND PARALLEL IMPORTERS MUST PAY A FEE

Manufacturers and parallel importers with marketing authorisations in Denmark that wish to sell their medicinal products on the Danish market must pay an initial fee and a yearly verification fee to the DMVO. The yearly verification fee is a flat fee fixed at European level. The rules governing payment of fees are a consequence of the fact that the establishment and operation of the verification system must be financed by the manufacturers and parallel importers. The fees are to be paid from 2019.

FIVE TIPS ON THE VERIFICATION SYSTEM

  • The manufacturing should already now be prepared for the packagings being provided with bar codes and safety sealings from 19 February 2019.
  • Be aware that the new safety features do not replace the current requirements for labelling etc.
  • The marketing authorisation holders may conclude agreements with the DMVO from September 2017.
  • The safety features may be placed on the packagings prior to February 2019 when the verification system comes into force.
  • The procedure concerning uploading of product data to the EMVS is called On-boarding, and the manufacturers and parallel importers are called On-boarding-Partners (OBPs). For more information on the uploading procedure, see the EMVS' website.

Read more about the Directive

Read more about the regulation

contacts

related news

Price increases in the pharma sector may be considered abuse of a dominant position

13 February 2018

The Danish Competition Council ruled that CD Pharma had abused its dominant position by increasing the price on the medicinal product Syntocinon by 2,000 % in 2014.

Horten obtains top ranking in WTR1000

26 January 2018

World Trademark Review 1000 recently published its rankings for 2018. Once again, Horten obtained a top ranking.

Four new partners at Horten

16 January 2018

With effect from 1 January 2018, Horten appointed Christian Tullberg, Kristoffer Westberg, Christina Steen and Niels Jørgen Oggesen as partners.

Self-selection of OTC drugs

9 January 2018

From 1 January 2018, OTC drugs may be available for self-selection, which means that pharmacies and retailers may sell certain OTC drugs from shop areas and not only at the counter.

New Managing Partner at Horten

2 January 2018

Finn Schwarz, Attorney and Partner, has been appointed Managing Partner of Horten Law Firm as of 1 January 2018.

Judgment in the Coty case: Prohibition against use of third party's online platform was not unlawful

12 December 2017

On 6 December 2017, the European Court of Justice ruled that cosmetics manufacturer Coty's prohibition against internet sale via third parties was not unlawful.

New recommendations for the implementation of the Clinical Trial Regulation

14 November 2017

The European Commission has recently published three recommendations for the implementation of regulation (EU) No 536/2014 on clinical trials on medical products for human use (the Clinical Trial Regulation).

New executive order regarding cannabis out for consultation

3 October 2017

Last week, a draft executive order on import of cannabis starting materials and the subsequent manufacturing of cannabis intermediate products went out for consultation.

Green Tech Challenge 2017

27 September 2017

Horten supports the Green Tech Challenge with a team of advisors and a financial contribution. The Green Tech Challenge supports a number of selected Nordic tech companies with a strong sustainable agenda to optimise their businesses.

Compliance: E-leaning in competition law

20 September 2017

Horten now offers e-learning in competition law tailored to each company.

Horten advances in new Chambers and Legal 500 rankings

19 April 2017

In 2017, the leading international ranking agencies, Legal 500 and Chambers, are once again ranking Horten among the best law firms in Denmark.

Comparative markets - supermarkets and hypermarkets

9 March 2017

The CJEU recently issued its ruling in case C-562/15 on comparative advertising comparing prizes between shops of different sizes and formats.

New action plan for the implementation of the regulation on data protection

30 January 2017

The Article 29 group has adopted a new action plan listing which subjects the group will prioritise in 2017 to ensure an effective implementation of the regulation on data protection.

Data protection officer – who, when, what?

12 January 2017

The so-called Article 29 group has adopted a set of guidelines covering data protection officers, which will provide more clarity with regard to the data protection officer's assignments, position and liability.

Global Leaders in Law appoints Horten as exclusive partner for Denmark

10 January 2017

Global Leaders in Law, the leading global general counsel forum based in London, and Horten has announced partnership. Appointed as a global bronze partner, Horten will sponsor the activities of Global Leaders in Law in 2017.

Greenland adopts personal data act

22 November 2016

From 1 December 2016, the Personal Data Act became effective in Greenland at the request of the Greenland Home Rule. The Act replaces the data protection legislation from 1978, which has applied in Greenland until now.

Internet media under pressure because of new EU ruling

15 September 2016

The latest ruling on hyper links and copyright confirms previous case law and adds a new rule of presumption, which may threaten the existence of some Internet media.

Circle K wins over OK in legal action concerning a new logo - Horten assisted Circle K

25 August 2016

Horten has assisted Circle K in a legal action against OK. OK claimed that Circle K's new logo infringed the company's trademark rights to OK and was therefore contrary to the Trademark Act.

New rules on trade secrets in the pipeline

27 June 2016

At the end of 2013, the European Commission presented a draft directive on the legal protection of trade secrets. After more than two years' negotiations between the European Commission, the European Parliament and the Member States, political agreement was reached on a final draft shortly before Christmas. The revised directive was finally adopted by the Council on 26 May 2016.

Horten is promoted to the gold tier for 2016 in IAM Patent 1000

8 June 2016

Glowing reports from peers and patrons see Horten promoted to the gold tier for 2016. It is “a force to be reckoned with in high-stakes litigation”.

Eckes-Granini acquires Rynkeby Foods A/S

19 May 2016

German-based Eckes-Granini Group GmbH (‘Eckes-Granini’), the leading producer of branded fruit-based beverages in Europe, has on 18 May 2010 acquired Rynkeby Foods A/S.

New ratings from the international reference book Legal 500

4 May 2016

There are several good news for Horten in the new rankings, among these to new Tier 1-ratings in Media & entertainment and Telecoms.

Final adoption of the new personal data regulation

14 April 2016

The European Parliament has adopted the new personal data regulation together with the rest of the data protection reform.

International women lawyers discuss the future of the legal profession

6 April 2016

Horten participates when 150 lawyers from all over the world meet in Berlin on 7-8 April under the headline "Law in a changing world – how women can contribute to innovation of the legal profession".

Horten Corporate Day 2016 - Danish companies at the forefront

18 March 2016

At Horten's Corporate Day 2016 on 16 March, Danish and foreign executives and experts gave their views on the trends and opportunities of the Danish business sector. Horten will repeat the success next year with Horten Corporate Day 2017.

The Eastern High Court: Label infringes design right

9 February 2016

Horten represented the manufacturer of a diaper pail, Sangenic, and the High Court ruled that the use of a picture of the design-protected pail constituted an infringement of the design right.